As antibiotic-resistant "superbugs" make infections trickier to treat, some in the medical community are turning to ...

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance ...

Brii Biosciences Limited ("Brii Bio," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today ...

The growth of the complicated urinary tract infections market is expected to be mainly driven by the entry of new therapies such as Tebipenem Pivoxil Hydrobromide (SPR994), ZAYNICH ...

The main pharmacological interventions for palliation of breathlessness would be opioids, ie, oromorph and benzodiazepines ...